What is Sutro Biopharma (STRO) stock price today?

Sutro Biopharma (STRO) currently trades at $35.39 per share. The stock has a market capitalization of $556.51M and a P/E ratio of —x.

Is STRO stock a buy, sell, or hold in 2026?

Based on WallStSmart's proprietary analysis, Sutro Biopharma has a Smart Value Score of 23/100 (Grade F), resulting in a "Strong Sell" investment rating. The Piotroski F-Score is —/9 and Altman Z-Score is —.

What is Sutro Biopharma's revenue and earnings?

Sutro Biopharma has trailing twelve-month (TTM) revenue of $102.48M with profit margins of -186.50%. Earnings per share (EPS) is $-22.49.

Is STRO stock overvalued or undervalued?

Based on our DCF model, Sutro Biopharma's intrinsic value is $60.45, representing a margin of safety of 73.98%. The stock currently trades at a P/E of —x.

STRO

Sutro Biopharma

NASDAQ: STRO · HEALTHCARE · BIOTECHNOLOGY

$35.39

+2.02% today

Updated 2026-04-29

Market cap

$556.51M

P/E ratio

—

P/S ratio

5.43x

EPS (TTM)

$-22.49

Dividend yield

—

52W range

$7 – $36

Volume

0.2M

Market cap

$556.51M

P/E ratio

—

P/S ratio

5.43x

EPS (TTM)

$-22.49

Dividend yield

—

52W range

$7 – $36

Volume

0.2M

WallStSmart proprietary scores

out of 100

Grade: F

Strong Sell

Investment rating

4.7

Growth

5.0

Quality

C+

2.0

Profitability

6.7

Valuation

—/9

Piotroski F-Score

—

Altman Z-Score

—

Industry rank

—

View all highly rated stocks (75+) →200 stocks currently score above 75

Price targets

Analyst target

$32.11

-9.27%

12-Month target

—

Intrinsic (DCF)

$60.45

Margin of safety

+73.98%

2 Strong Buy6 Buy1 Hold0 Sell1 Strong Sell

Price chart

X-Ray snapshot

Strengths

+ 73.98% below intrinsic value

Risks

- Thin margins at -186.50%

- Negative free cash flow $-26.62M

- Revenue declining -21.40% QoQ

Key financials

Revenue Net Income Free Cash Flow

Metric	2022	2023	2024	2025	TTM
Revenue	$67.77M	$153.73M	$62.04M	$102.48M	$102.48M
Net income	$-119.20M	$-106.79M	$-227.46M	$-191.09M	$-46.76M
EPS	—	—	—	—	$-22.49
Free cash flow	$-4.31M	$-115.93M	$-194.64M	$-178.93M	$-26.62M
Profit margin	-175.89%	-69.47%	-366.62%	-186.45%	-186.50%

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
STRO	$556.51M	23	4.7	2.0	6.7	5.0	+73.98%	Avoid
LLY	$789.69B	78	10.0	10.0	5.0	6.5	—	Strong Buy
JNJ	$547.64B	59	4.7	9.0	3.3	6.0	-41.97%	Buy
ABBV	$351.47B	63	4.0	8.0	4.7	5.0	-24.92%	Buy
UNH	$322.34B	54	5.3	5.5	7.3	4.8	+42.06%	Buy
AZN	$294.17B	64	6.7	8.0	5.3	5.0	+4.07%	Buy

Smart narrative

Sutro Biopharma trades at $35.39. Our Smart Value Score of 23/100 indicates the stock is weak. TTM revenue stands at $102.48M. with profit margins at -186.50%. Our DCF model estimates intrinsic value at $60.45.

Frequently asked questions

What is Sutro Biopharma's stock price?

Sutro Biopharma (STRO) trades at $35.39.

Is Sutro Biopharma overvalued?

Smart Value Score 23/100 (Grade F, Strong Sell). DCF value $60.45.

What is the price target of Sutro Biopharma (STRO)?

The analyst target price is $32.11, representing -9.3% downside from the current price of $35.39.

What is the intrinsic value of Sutro Biopharma (STRO)?

Based on our DCF model, intrinsic value is $60.45, a +74.0% margin of safety versus $35.39.

What is Sutro Biopharma's revenue?

TTM revenue is $102.48M.

Company info

SectorHEALTHCARE

IndustryBIOTECHNOLOGY

CountryUSA

ExchangeNASDAQ

CurrencyUSD

Quick metrics

P/S ratio5.43x

ROE-1,810.00%

Beta1.31

50D MA$24.52

200D MA$13.65

Shares out0.02B

Float0.01B

Short ratio—

Avg volume0.2M

Performance

1 week-2.36%

1 month+43.94%

3 months+122.23%

YTD+199.83%

1 year—

3 years—

5 years—

Compare

STRO vs LLY →STRO vs JNJ →STRO vs ABBV →Stock screener →